Did the beneficial renal outcomes with vasopressin VANISH?

Affiliations

Comment

Gretchen L Sacha et al. Ann Transl Med. 2016 Oct.

. 2016 Oct;4(Suppl 1):S67.

doi: 10.21037/atm.2016.10.59.

No abstract available

Conflict of interest statement

The authors have no conflicts of interest to declare.

Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial.
Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, Pogson DG, Aya HD, Anjum A, Frazier GJ, Santhakumaran S, Ashby D, Brett SJ; VANISH Investigators. Gordon AC, et al. JAMA. 2016 Aug 2;316(5):509-18. doi: 10.1001/jama.2016.10485. JAMA. 2016. PMID: 27483065 Clinical Trial.

1. Lagu T, Rothberg MB, Shieh MS, et al. Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med 2012;40:754-61. 10.1097/CCM.0b013e318232db65 - DOI - PubMed
1. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637. 10.1097/CCM.0b013e31827e83af - DOI - PubMed
1. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-87. 10.1056/NEJMoa067373 - DOI - PubMed
1. Russell JA, Walley KR, Gordon AC, et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 2009;37:811-8. 10.1097/CCM.0b013e3181961ace - DOI - PubMed
1. Nakada TA, Russell JA, Wellman H, et al. Leucyl/cystinyl aminopeptidase gene variants in septic shock. Chest 2011;139:1042-9. 10.1378/chest.10-2517 - DOI - PubMed